Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
AUR-107
i
Other names:
AUR-107, AUR107, AUR 107
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Dr. Reddy’s
Drug class:
CBP inhibitor, EP300 inhibitor
Related drugs:
‹
eribulin mesylate (47)
PRI724 (5)
CCS1477 (4)
FT-6876 (1)
AU-18069 (0)
E7386 (0)
EP31670 (0)
NEO1132 (0)
eribulin mesylate (47)
PRI724 (5)
CCS1477 (4)
FT-6876 (1)
AU-18069 (0)
E7386 (0)
EP31670 (0)
NEO1132 (0)
›
Associations
News
Trials
Filter by
Latest
almost2years
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) (clinicaltrials.gov)
P1, N=50, Recruiting, Aurigene Discovery Technologies Limited | Not yet recruiting --> Recruiting
almost 2 years ago
Enrollment open
|
MUC16 (Mucin 16, Cell Surface Associated)
|
AUR-107
over2years
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1) (clinicaltrials.gov)
P1, N=50, Not yet recruiting, Aurigene Discovery Technologies Limited
over 2 years ago
New P1 trial • Metastases
|
AUR-107
Share via
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.